NEWSROOM
Discover all the actions carried out by Jeito and all the partnerships that we set up day after day for the well-being of patients and medical progress.
In the headlines
Jeito Capital Makes Significant Investment in the Second Closing of Alveus Therapeutics’ Oversubscribed Series A, Bringing Total Financing to $197 Million
Proceeds from the financing will advance the Phase 2 clinical development of Alveus’ lead program ALV‑100 designed to deliver potent, durable weight loss and long‑term maintenance with improved tolerability. The financing will also support Investigational New Drug...
Download our White Paper
We are pleased to share with you our White Paper, which offers a deep dive into the evolving biopharma landscape and highlights the key trends shaping its future.
Find all our press releases
EyeBio Announces Positive Visual, Anatomic and Safety Data from First-in-Human Ph1b/2a AMARONE Trial of Restoret at Macula Society Annual Meeting
Twelve week data from the Ph1b/2a AMARONE trial reveals Restoret to be well-tolerated in patients...
Jeito Capital participates in a $95 Million financing for HI-Bio™, a US-based clinical-stage biopharma company developing targeted therapies for patients with severe immune-mediated diseases
One year after its first investment, this new significant participation in HI-Bio™’s Series B...
Jeito Capital portfolio company Advesya emerges from stealth mode with the potential to become a leader in the treatment of hematological malignancies and other tumor treatments
Paris, France, 3 January 2024 - Jeito Capital ("Jeito"), a global leading independent private...
Jeito Capital announces appointment of new Partner Investor Ksenija Pavletic
Paris, France, 3 January 2024 - Jeito Capital ("Jeito"), a global leading independent private...
Jeito Capital creates a community of leading international Special Advisors to complement its extensive sets of skills and further extend its support to portfolio companies
Paris, France, November 29th 2023 - Jeito Capital (“Jeito”), a leading global investment company...
Jeito Capital leads €75 million Series B Financing in NMD Pharma, a Danish company, to develop breakthrough treatments for patients with severe neuromuscular diseases
Jeito Capital’s second round of funding will support NMD Pharma in becoming a leading, global,...
Face to face
Meet Jeito
12-15
January
All day long
JPM Healthcare Conference 2026
Jeito will be present at the 44th JPM Healthcare Conference 2026, renowned as the largest and most influential healthcare investment symposium, attracting global industry leaders, Biotech companies, and members of the investment community, in San Francisco.